Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Genocea Biosciences stock

Learn how to easily invest in Genocea Biosciences stock.

Genocea Biosciences Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 74 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Genocea Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GNCA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Genocea Biosciences stock price (NASDAQ: GNCA)

Use our graph to track the performance of GNCA stocks over time.

Genocea Biosciences shares at a glance

Information last updated 2022-06-30.
Latest market close$0.02
52-week range$0.01 - $2.27
50-day moving average $0.13
200-day moving average $0.98
Wall St. target price$3.08
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.53

Buy Genocea Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genocea Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genocea Biosciences price performance over time

Historical closes compared with the close of $0.015 from 2022-07-01

1 week (2022-06-28) -8.54%
1 month (2022-06-01) -75.00%
3 months (2022-04-05) -98.88%
6 months (2022-01-05) -98.57%
1 year (2021-07-02) -99.33%
2 years (2020-07-02) -99.32%
3 years (2019-07-05) 3.83
5 years (2017-07-05) 5.27

Genocea Biosciences financials

Revenue TTM $1.9 million
Gross profit TTM $1.6 million
Return on assets TTM -57.59%
Return on equity TTM -525.78%
Profit margin 0%
Book value $0.21
Market capitalisation $999,319

TTM: trailing 12 months

Genocea Biosciences share dividends

We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.

Have Genocea Biosciences's shares ever split?

Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.

Genocea Biosciences share price volatility

Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $0.012 up to $2.27. A popular way to gauge a stock's volatility is its "beta".

GNCA.US volatility(beta: 1.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.9474. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Genocea Biosciences overview

Genocea Biosciences, Inc. , a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Genocea Biosciences is owned by insiders or institutions?
Currently 6.222% of Genocea Biosciences shares are held by insiders and 40.931% by institutions.
How many people work for Genocea Biosciences?
Latest data suggests 74 work at Genocea Biosciences.
When does the fiscal year end for Genocea Biosciences?
Genocea Biosciences's fiscal year ends in December.
Where is Genocea Biosciences based?
Genocea Biosciences's address is: 100 Acorn Park Drive, Cambridge, MA, United States, 02140
What is Genocea Biosciences's ISIN number?
Genocea Biosciences's international securities identification number is: US3724274010
What is Genocea Biosciences's CUSIP number?
Genocea Biosciences's Committee on Uniform Securities Identification Procedures number is: 372427104

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site